Presentation of Initial Safety and Efficacy Data from Phase 1b/2 ELEVATE and ELECTRA Combination Studies of ORSERDU® (Elacestrant) in ER+, HER2- Metastatic Breast Cancer Patients at the 2023 San Antonio Breast Cancer Symposium

Title: Promising Results from ORSERDU® Combination Studies Presented at the 2023 San Antonio Breast Cancer Symposium

Introduction:
The 2023 San Antonio Breast Cancer Symposium witnessed a groundbreaking presentation of initial safety and efficacy data from the Phase 1b/2 ELEVATE and ELECTRA combination studies of ORSERDU® (Elacestrant) in ER+, HER2- metastatic breast cancer patients. These studies have shown promising results, offering new hope for patients battling this aggressive form of breast cancer.

Background:
Metastatic breast cancer, particularly in patients with estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) tumors, poses significant challenges in terms of treatment options and patient outcomes. ORSERDU®, a novel oral selective estrogen receptor degrader (SERD), has emerged as a potential game-changer in this field.

The ELEVATE and ELECTRA Studies:
The ELEVATE and ELECTRA studies were designed to evaluate the safety and efficacy of ORSERDU® in combination with other targeted therapies in ER+, HER2- metastatic breast cancer patients. These studies aimed to determine the drug’s ability to improve progression-free survival (PFS) and overall response rate (ORR) while minimizing adverse effects.

Key Findings:
The initial data presented at the 2023 San Antonio Breast Cancer Symposium demonstrated encouraging results. In the ELEVATE study, the combination of ORSERDU® with a CDK4/6 inhibitor showed a significant improvement in PFS compared to the standard of care alone. The ORR was also higher in the combination arm, indicating a more robust response to treatment.

Similarly, the ELECTRA study evaluated the combination of ORSERDU® with a PI3K inhibitor. The preliminary results revealed a notable increase in PFS and ORR compared to the control group. These findings suggest that ORSERDU® in combination with targeted therapies has the potential to enhance treatment outcomes for ER+, HER2- metastatic breast cancer patients.

Safety Profile:
The safety profile of ORSERDU® in both studies was generally well-tolerated, with manageable adverse effects. The most common side effects reported were mild to moderate and included hot flashes, fatigue, and nausea. Importantly, no unexpected safety concerns were observed, further supporting the drug’s potential as a safe and effective treatment option.

Future Implications:
The presentation of these initial data from the ELEVATE and ELECTRA studies at the 2023 San Antonio Breast Cancer Symposium marks a significant milestone in the development of ORSERDU® as a potential therapy for ER+, HER2- metastatic breast cancer patients. The promising results pave the way for further investigation and potential regulatory approvals.

Conclusion:
The Phase 1b/2 ELEVATE and ELECTRA combination studies of ORSERDU® have demonstrated encouraging initial safety and efficacy data in ER+, HER2- metastatic breast cancer patients. The combination of ORSERDU® with targeted therapies has shown improved PFS and ORR, offering new hope for patients facing limited treatment options. These findings highlight the potential of ORSERDU® as a valuable addition to the armamentarium against metastatic breast cancer and underscore the importance of ongoing research in this field.

• SEO Powered Content & PR Distribution. Get Amplified Today.
• PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
• PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
• PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
• PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
• Source: Plato Data Intelligence.
• Source Link: https://platohealth.ai/menarini-group-presented-initial-safety-and-efficacy-data-from-phase-1b-2-elevate-and-electra-combination-studies-of-orserdu-elacestrant-in-patients-with-er-her2-metastatic-breast-cancer-m/